A phase II trial of ifosphamide for patients with previously treated small cell lung cancer

UMIN ID: UMIN000002465

Registered date:07/09/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: previously treated small cell lung cancer
• Date of first enrollment: 2009/07/01
• Target sample size: 20
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Ifosphamide

Outcome(s)

• Primary Outcome: Response rate
• Secondary Outcome: Progression free survival median survival time Safety(incidence of adverse event)

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 75years-old
• Gender: Male and Female
• Exclude criteria: 1 severe pleural, pericardial effusion, ascites or supra vena cava syndrome 2 sever complication(severe cardiac disease, heart failure, myocardial infarction and angina pectoris within the last 6 months, cerebrovascular disease within the last 6 months, poorly controlled hypertension, active infection)and another active cancer 3 symptomatic brain metastases 4 pregnancy, intent to became pregnant,or breast-feeding 5 active psychological disease 6 non eligible cases judged by investigators

Related Information

• Primary Sponsor: Nagoya University Hospital
• Secondary Sponsor: Nagoya first red cross hospital
• Source(s) of Monetary Support: None